Medical Condition

interstitial lung disease

Total Trials

8

Recruiting Now

8

Trial Phases

Phase 2, Phase 3

Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.

Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.

Frequently Asked Questions — interstitial lung disease Clinical Trials

How many clinical trials are currently recruiting for interstitial lung disease?

ClinicalMetric currently tracks 8 actively recruiting clinical trials for interstitial lung disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for interstitial lung disease?

interstitial lung disease research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a interstitial lung disease clinical trial?

Eligibility criteria for interstitial lung disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

Phase 3

Top Sponsors

Centre hospitalier de l'Université de Montréal (CHUM) 1 trial

University Hospital, Tours 1 trial

United Therapeutics 1 trial

Liquidia Technologies, Inc. 1 trial

Berner Reha Zentrum AG 1 trial

Recruiting Clinical Trials

NCT05785065 Phase 2

Recruiting

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

Centre hospitalier de l'Univer...

View Trial →

NCT06235645

Recruiting

dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound

University Hospital, Tours

View Trial →

NCT05943535 Phase 3

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Enrollment

698 pts

Location

United States, Argen...

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Liquidia Technologies, Inc.

View Trial →

NCT06027333

Recruiting

Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease

Berner Reha Zentrum AG

View Trial →

NCT06577753

Recruiting

REspiratory diSEAse cohoRt Studies of CHinese Medicine for ILD (RESEARCH-ILD)

Henan University of Traditiona...

View Trial →

NCT01280994 Phase 2

Recruiting

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis

Guang'anmen Hospital of China ...

View Trial →

Related Conditions

systemic sclerosis with lung involvement (1) systemic sclerosis (1) rheumatoid arthritis (1) thoracic ultrasound (1) lung ultrasound (1) progressive pulmonary fibrosis (1) pulmonary hypertension (1) fibrotic lung disease (1) self efficacy (1) self management (1) patient education (1) quality of life (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology